Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the metabolic dysfunction-associated steatohepatitis (mash) treatment market right now?
In the past few years, the market size for metabolic dysfunction-associated steatohepatitis (MASH) treatment has experienced significant growth. The market is projected to expand from $2.00 billion in 2024 to $2.60 billion in 2025, with a compound annual growth rate (CAGR) of 30.0%. The surge in the historic period can be attributed to factors like the increasing incidence of non-alcoholic steatohepatitis, contemporary dietary trends favoring processed foods, sedentary lifestyles, and a growing prevalence of metabolic disorders.
How fast Is the metabolic dysfunction-associated steatohepatitis (mash) treatment market expected to grow, and what’s its future value?
The market size for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH) is predicted to undergo significant expansion in the years to come, increasing to a value of $7.38 billion by 2029, with a compound annual growth rate (CAGR) of 29.8%. This anticipated growth during the forecast period can be linked to the rising incidences of obesity and diseases related to obesity, alongside early interventions, effective reimbursement strategies, insurance benefits, and an increased cognizance of liver ailments. The forecast period is also set to witness several major trends like advancements in technology, development in pipeline, strategic alliances and partnerships, the emergence of personalized medicine and precision therapeutics, and a marked increase in investment towards research and clinical trials.
Get your metabolic dysfunction-associated steatohepatitis (mash) treatment market report here!
What are the leading drivers of growth in the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
The escalating incidence of obesity is projected to spur the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market. Obesity, a health condition marked by an undue buildup of body fat that can unfavourably affect overall health, is commonly gauged by a body mass index (BMI) of 30 or above. Sedentary lifestyles, unhealthy food habits, and metabolic risk elements are driving up the global prevalence of obesity. The treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in obesity focuses on dealing with insulin resistance, minimizing liver fat, and boosting metabolic health via lifestyle amendments and specific therapies. For instance, the World Heart Foundation, a non-government international cardiovascular society based in Switzerland reported in March 2023 that currently, around 2.3 billion adults and children worldwide are obese or overweight, and in light of the continued obesity trend, this number is expected to hit 2.7 billion by 2025. Hence, the escalating incidence of obesity is fuelling growth in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
What are the key segments defining the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market covered in this report is segmented –
1) By Treatment: By Drug, By Therapy
2) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists, Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
Who are the key players steering the development of the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals
How are evolving market trends shaping metabolic dysfunction-associated steatohepatitis (mash) treatment Strategies?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are focusing on developing innovative products such as liver fibrosis treatment solutions to provide the treatment option for patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe liver fibrosis. Liver fibrosis treatment solutions focus on addressing the underlying causes of liver damage through lifestyle modifications, antiviral medications, and emerging antifibrotic therapies, aiming to halt or reverse the progression of fibrosis and improve liver function. For instance, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced the FDA approval of Rezdiffra (resmetirom), the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra is a daily oral tablet that demonstrated efficacy in resolving MASH without worsening fibrosis and improving liver fibrosis in phase 3 clinical trials. This breakthrough offers a non-invasive treatment alternative, eliminating the need for liver biopsies, and significantly improves patient access and outcomes in managing fatty liver disease.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20876
Which regions are most influential in expanding the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Metabolic Disorders Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Global Cardiometabolic Diseases Global Market Report 2025
https://thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
Comprehensive Metabolic Panel Testing Global Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
